The randomised, double-blind multi-center Phase III study was conducted in patients with advanced hepatocellular carcinoma (HCC), who have not received prior systemic treatment. Bristol-Myers Squibb global development and
Rebamipide ophthalmic suspension has a new mechanism of action to increase the level of mucin in the tear film covering the conjunctiva and cornea. The drug was launched
PAREXEL enhances development network and will provide access to a range of drug development support services, which are customized to meet the needs of Korean national companies and
BZA/CE is designed for postmenopausal women with a uterus for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture. The company said BZA/CE
As part of the contract, Clinipace Worldwide will study Proleukin (aldesleukin) and Vemurafenib therapy in patients with metastatic melanoma (mM). The study with a sample size of 135
The $102.5m worth contract will help the National Institute of Allergy and Infectious Diseases (NIAID) Division of Microbiology and Infectious Diseases (DMID) to develop medical countermeasures against infectious
The integrated oncology data solution will provide promotional spending combined with actual drug usage data across a significant sample of US Oncologists. The technology will allow pharmaceutical marketers
BergaMet MEGA, which contains bergamot dehydrated juice and ascorbic acid, is designed for targeting cholesterol, blood pressure, blood glucose and abdominal obesity, the major components of metabolic syndrome,
According to the agreement, both the organizations will conduct proof-of-concept, safety and functional studies for immunomodulatory approach to treat type 1 diabetes. Sanofi global diabetes senior vice president
The objective of the collaboration is to gain knowledge about the fundamental genetic causes of ALS. As per the agreement, Biogen Idec will fund the project at the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.